Boehringer Ingelheim’s Post

Check out our recent findings in Nature Cancer on a promising new approach to target KRAS- driven cancers!

So important

Unraveling the Mysteries of p53 💡 Discover the world of TP53 mutations and their impact on cancer development and therapy! Our latest reading recommendation explores the secrets of p53, the most mutated gene in cancers affecting 50% of patients. 🔍  The article reviews the dual nature of p53: from tumor suppression to oncogenic activities, this protein might hold the key to unlocking groundbreaking therapies. 🧬🔬We at 4bases harness the power of TP53 alongside 94 other solid-tumor related genes in our PANCANCER pro kit, designed for easy, fast and precise molecular profiling of solid tumors. 👉 Click here to explore p53 and how it is shaping the landscape of cancer research: https://lnkd.in/d9fFBpqs #4bases #whenprecisionmatters #p53 #CancerResearch #MedicalBreakthroughs

#Nature Portfolio- Using cancer’s best weapon against it https://lnkd.in/dcKHfx34 Using cancer’s best weapon against it Researchers have discovered a gene mutation that naturally occurs inside cancerous T cells that can be used to strengthen therapeutic T cells designed to fight cancer. Both cancerous and therapeutic T cells face similar kinds of challenges to their survival, and the protein encoded by this mutant gene — CARD11–PIK3R3 — helps the T cells live longer and travel further inside tumours. When this cancer gene was incorporated into chimeric antigen receptor (CAR) T cells, a much smaller arsenal of these cells was required to melt solid and blood tumours in mice (20,000 cells instead of the usual one million). There’s a risk that the mutant gene will turn therapeutic T cells cancerous, but the animal data suggests the treatment is safe.

𝗔𝗻𝗮𝗹𝘆𝘇𝗲 𝘆𝗼𝘂𝗿 𝘁𝘂𝗺𝗼𝗿 𝘀𝗮𝗺𝗽𝗹𝗲𝘀 𝘂𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗧𝗿𝘂𝗦𝗶𝗴𝗵𝘁™ 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝟱𝟬𝟬 𝗔𝘀𝘀𝗮𝘆 This assay is a great option to comprehensively profile a tumor by analyzing 523 cancer-relevant genes. It detects single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variations (CNVs). Additionally, it assesses key cancer biomarkers: tumor mutational burden (TMB) and microsatellite instability (MSI). You can choose between different TSO500 products for comprehensive genomic profiling of your tumor samples. Learn more on our website: https://lnkd.in/em5sXhAQ #research #science #sequencing #oncology #tumor #cancer #genetics #TSO500

Enriching insight in patient responses to targeted therapies by ex vivo tumor testing. VitroScan's Lieke Ceton and Timothy Sijsenaar will present our newest data on patients sensitivity to targeted therapies at the European Association for Cancer Research (EACR) - Innovative Cancer Science Cogress '24. Accumulating evidence indicates that a direct correlation between a mutated cancer gene and a response to a given therapy is too simplistic. Ex vivo tumor testing preserves the overall complexity of the tissue and cellular pathways that elicit response to treatment thus providing near patient testing. In addition, it assesses the response to targeted therapies in the context of the patients sensitivity to other drug classes in parallel. We are looking forward to connect during the meeting potentially via a discussion at the posters find us Tuesday 11 June 2024 - EACR2024-#0808. #EACR24, #targetedtherapy, #predictivetesting, #cancerresearch

Additional data supporting MammaPrint® utility in treatment selection will be presented in a #ASCO24 poster by other investigators titled “Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancer Closely Resembles Triple Negative Breast Cancer: Results from Gene Expression Data from the ISPY2 Trial” [Rios-Hoyo, A., et al.]. Attend the poster session presentation on June 2nd from 9:00am – 12:00pm CT. View the poster here: https://lnkd.in/gFYypyMQ #ASCO24 #oncology #breastcancer

For #TrialTuesday, Alliance A022106/PLATINUM trial, led by Dr. Andrew Ko, of UCSF Helen Diller Family Comprehensive Cancer Center, compares two chemotherapy regimens to treat patients with metastatic #pancreaticcancer and BRCA1/2 or PALB2 gene mutation. To learn more about the PLATINUM trial, visit https://lnkd.in/gq9nYKxM #NCI #NCTN Pancreatic Cancer Action Network Let's Win Pancreatic Cancer #PancChat #PancSM

Innovative strides in cancer research: A team from MIT has introduced a rapid screening method using CRISPR's prime editing to examine the effects of cancer mutations. This technique holds the promise of accelerating the discovery of targeted cancer treatments, offering a deeper insight into tumor development and therapy response. A significant advancement in precision medicine. https://loom.ly/CaqMRW0 #cancerresearch #geneediting #crispr #primediting #precisionmedicine #oncologyresearch

🌍 On World Cancer Research Day, we reaffirm our commitment to pioneering breakthroughs in cancer treatment.   Our focus is on selectively targeting mutant p53, a critical gene in many cancers. By honing in on specific mutation, we aim to fundamentally disrupt the course of cancer, with the aim of offering hope and innovative therapies to patients worldwide.   Our research is dedicated to providing unique solutions for those whose tumors harbor these gene mutations.   Together, let's push the boundaries of what's possible in cancer research.   #WorldCancerResearchDay #InnovativeTherapies